Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598329 | 0.87 | CYP1A2 (0.49) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL25547803 | 0.85 | CYP1A2 (0.55) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL7927384 | 0.84 | CYP1A2 (0.59) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29191678 | 0.82 | CYP1A2 (0.52) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL79573 | 0.80 | UGT2B7 (0.42) | CYP1A2CYP2A6ALDH1A1HPGDLMNA | |
| SCHEMBL596870 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL31553088 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL29355679 | 0.79 | CYP1A2 (0.49) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL28295455 | 0.79 | ALDH1A1 (0.56) | CYP1A2CYP2A6ALDH1A1HPGDHSD17B10 | |
| SCHEMBL11468163 | 0.79 | AKR1B1 (0.60) | CYP1A2CYP2A6PTGS1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190224193-A1 | Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases | REID CHRISTOPHER BRIAN (US) | 2019-07-25 | — | — | US | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| US-20140271923-A1 | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions | REID CHRISTOPHER BRIAN (US) | 2014-09-18 | — | — | US | claimed |
| WO-2007066305-A1 | COMPOSITIONS COMPRISING SESQUITERPENE COMPOUNDS FOR USE IN THE PROPHYLAXIS OR TREATMENT OF PAIN | ZELPY 2549 (PTY) LIMITED (ZA) | 2007-06-14 | — | — | WO | claimed |
| US-4408083-A | SOLVENT EXTRACTION, THERMAL DECOMPOSITION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1983-10-04 | — | — | US | claimed |
| US-20260048023-A1 | LIPID NANOPARTICLE COMPRISING A DNA-BINDING PROTEIN | SEQIRUS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4572740-A1 | LIPID NANOPARTICLE COMPRISING A DNA-BINDING PROTEIN | Seqirus Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20240398941-A1 | LIPID NANOPARTICLE COMPRISING A NUCLEIC ACID-BINDING PROTEIN | Seqirus Inc. | 2024-12-05 | — | — | US | disclosed |
| WO-2024209404-A1 | RNA DELIVERY VEHICLE | Seqirus Inc. (US) | 2024-10-10 | — | — | WO | disclosed |
| EP-4412592-A1 | LIPID NANOPARTICLE COMPRISING A NUCLEIC ACID-BINDING PROTEIN | Seqirus Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024038407-A1 | LIPID NANOPARTICLE COMPRISING A DNA-BINDING PROTEIN | Seqirus Inc. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2023057935-A1 | LIPID NANOPARTICLE COMPRISING A NUCLEIC ACID-BINDING PROTEIN | Seqirus Inc. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-5639922-A | CONTACTING AROMATIC PRIMARY AND TERTIARY HYDROPEROXIDES MIXTURE OBTAINED BY OXIDATION OF ALKYLAROMATIC COMPOUNDS WITH AN ALKALI OR ALKALINE ORGANIC AROMATIC CARBOXYLIC ACID SALT, DECOMPOSING WITH ACID CATALYST FORMING ALKYL PHENOLS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-06-17 | — | — | US | disclosed |
| CN-1128754-A | Method for treatment of mixture of hydroperoxide | SUMITOMO CHEMICAL CO (JP) | 1996-08-14 | — | — | CN | disclosed |
| US-5166451-A | Peroxide mixture and quaternary ammonium salt for reducing the content of primary hydroperoxides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1992-11-24 | — | — | US | disclosed |
| CN-1009927-B | Treatment of hydroperoxide mixtures | SUMITOMO CHEMICAL CO (JP) | 1990-10-10 | — | — | CN | disclosed |
| CN-87105264-A | The processing of hydroperoxide mixture | — | 1988-05-18 | — | — | CN | disclosed |
| EP-0046405-B1 | METHOD OF TREATING HYDROPEROXIDE MIXTURES | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1984-07-11 | — | — | EP | disclosed |
| US-4408083-A | SOLVENT EXTRACTION, THERMAL DECOMPOSITION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1983-10-04 | — | — | US | disclosed |
| EP-0046405-A1 | Method of treating hydroperoxide mixtures | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048023-A1 | LIPID NANOPARTICLE COMPRISING A DNA-BINDING PROTEIN | SREBF1, SREBF2, CNBP | CYP1A2 4861/4885CYP2A6 4772/4885ALDH1A1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.